Click Here to return To Results

 

A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa NEJM 342:1484-1491, Rascol,O.,et al, 2000 See this aricle in Pubmed Article Abstract At five years, the cumulative incidence of dyskinesia (excluding the three patients who had dyskinesia at base line), regardless of levodopa supplementation, was 20 percent (36 of 177 patients) in the ropinirole group and 45 percent (40 of 88 patients) in the levodopa group. There was no significant difference between the two groups in the mean change in scores for activities of daily living among those who completed the study. Adverse events led to the early withdrawal from the study of 48 of 179 patients in the ropinirole group (27 percent) and 29 of 89 patients in the levodopa group (33 percent). The mean (+/=SD) daily doses given by the end of the study were 16.5+/=6.6 mg of ropinirole (plus 427+/=221 mg of levodopa in patients who received supplementation) and 753+/=398mg of levodopa (including supplements). Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction dopamine agonist dyskinesia L-dopa L-dopa,drug interactions with and side effects of movement disorder,drug induced Parkinson disease Parkinson disease,treatment of ropinirole treatment of neurologic disorder

Click Here to return To Results